392 related articles for article (PubMed ID: 16009830)
1. A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes.
Suhler EB; Smith JR; Wertheim MS; Lauer AK; Kurz DE; Pickard TD; Rosenbaum JT
Arch Ophthalmol; 2005 Jul; 123(7):903-12. PubMed ID: 16009830
[TBL] [Abstract][Full Text] [Related]
2. Adalimumab therapy for refractory uveitis: results of a multicentre, open-label, prospective trial.
Suhler EB; Lowder CY; Goldstein DA; Giles T; Lauer AK; Kurz PA; Pasadhika S; Lee ST; de Saint Sardos A; Butler NJ; Tessler HH; Smith JR; Rosenbaum JT
Br J Ophthalmol; 2013 Apr; 97(4):481-6. PubMed ID: 23376607
[TBL] [Abstract][Full Text] [Related]
3. Infliximab in the treatment of refractory posterior uveitis.
Joseph A; Raj D; Dua HS; Powell PT; Lanyon PC; Powell RJ
Ophthalmology; 2003 Jul; 110(7):1449-53. PubMed ID: 12867408
[TBL] [Abstract][Full Text] [Related]
4. Adalimumab therapy for refractory uveitis: a pilot study.
Diaz-Llopis M; García-Delpech S; Salom D; Udaondo P; Hernández-Garfella M; Bosch-Morell F; Quijada A; Romero FJ
J Ocul Pharmacol Ther; 2008 Jun; 24(3):351-61. PubMed ID: 18476805
[TBL] [Abstract][Full Text] [Related]
5. Retrospective case review of pediatric patients with uveitis treated with infliximab.
Rajaraman RT; Kimura Y; Li S; Haines K; Chu DS
Ophthalmology; 2006 Feb; 113(2):308-14. PubMed ID: 16406545
[TBL] [Abstract][Full Text] [Related]
6. Long-term safety and efficacy of infliximab therapy in refractory uveitis due to Behçet's disease.
Abu El-Asrar AM; Abboud EB; Aldibhi H; Al-Arfaj A
Int Ophthalmol; 2005 Jun; 26(3):83-92. PubMed ID: 17031510
[TBL] [Abstract][Full Text] [Related]
7. Long-term clinical outcomes in patients with refractory uveitis associated with Behçet disease treated with infliximab.
Al Rashidi S; Al Fawaz A; Kangave D; Abu El-Asrar AM
Ocul Immunol Inflamm; 2013 Dec; 21(6):468-74. PubMed ID: 23734940
[TBL] [Abstract][Full Text] [Related]
8. Initial evaluation of subcutaneous daclizumab treatments for noninfectious uveitis: a multicenter noncomparative interventional case series.
Nussenblatt RB; Peterson JS; Foster CS; Rao NA; See RF; Letko E; Buggage RR
Ophthalmology; 2005 May; 112(5):764-70. PubMed ID: 15878055
[TBL] [Abstract][Full Text] [Related]
9. Long-term treatment of refractory posterior uveitis with anti-TNFalpha (infliximab).
Benitez-del-Castillo JM; Martinez-de-la-Casa JM; Pato-Cour E; Méndez-Fernández R; López-Abad C; Matilla M; Garcia-Sanchez J
Eye (Lond); 2005 Aug; 19(8):841-5. PubMed ID: 15389273
[TBL] [Abstract][Full Text] [Related]
10. Long-term efficacy of infliximab in refractory posterior uveitis of Behcet's disease: a 24-month follow-up study.
Niccoli L; Nannini C; Benucci M; Chindamo D; Cassarà E; Salvarani C; Cimino L; Gini G; Lenzetti I; Cantini F
Rheumatology (Oxford); 2007 Jul; 46(7):1161-4. PubMed ID: 17478466
[TBL] [Abstract][Full Text] [Related]
11. Anti-TNF-α therapy in patients with refractory uveitis due to Behçet's disease: a 1-year follow-up study of 124 patients.
Calvo-Río V; Blanco R; Beltrán E; Sánchez-Bursón J; Mesquida M; Adán A; Hernandez MV; Hernandez Garfella M; Valls Pascual E; Martínez-Costa L; Sellas-Fernández A; Cordero Coma M; Díaz-Llopis M; Gallego R; Salom D; García Serrano JL; Ortego N; Herreras JM; Fonollosa A; García-Aparicio AM; Maíz O; Blanco A; Torre I; Fernández-Espartero C; Jovani V; Peiteado-Lopez D; Pato E; Cruz J; Fernández-Cid C; Aurrecoechea E; García M; Caracuel MA; Montilla C; Atanes A; Hernandez FF; Insua S; González-Suárez S; Sánchez-Andrade A; Gamero F; Linares L; Romero-Bueno F; García AJ; Almodovar R; Minguez E; Carrasco Cubero C; Olive A; Vázquez J; Ruiz Moreno O; Jiménez-Zorzo F; Manero J; Muñoz Fernández S; Rueda-Gotor J; González-Gay MA
Rheumatology (Oxford); 2014 Dec; 53(12):2223-31. PubMed ID: 24996907
[TBL] [Abstract][Full Text] [Related]
12. Treating intraocular inflammatory disease in the 21st century.
Nussenblatt R
Arch Ophthalmol; 2005 Jul; 123(7):1000-1. PubMed ID: 16009844
[No Abstract] [Full Text] [Related]
13. Tumor necrosis factor alpha blockade with infliximab for refractory uveitis and scleritis.
Murphy CC; Ayliffe WH; Booth A; Makanjuola D; Andrews PA; Jayne D
Ophthalmology; 2004 Feb; 111(2):352-6. PubMed ID: 15019389
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behçet's disease: an open-label trial.
Tugal-Tutkun I; Mudun A; Urgancioglu M; Kamali S; Kasapoglu E; Inanc M; Gül A
Arthritis Rheum; 2005 Aug; 52(8):2478-84. PubMed ID: 16052571
[TBL] [Abstract][Full Text] [Related]
15. Loss of efficacy during long-term infliximab therapy for sight-threatening childhood uveitis.
Simonini G; Zannin ME; Caputo R; Falcini F; de Martino M; Zulian F; Cimaz R
Rheumatology (Oxford); 2008 Oct; 47(10):1510-4. PubMed ID: 18676502
[TBL] [Abstract][Full Text] [Related]
16. Infliximab therapy for the treatment of refractory ocular inflammatory disease.
Sobrin L; Kim EC; Christen W; Papadaki T; Letko E; Foster CS
Arch Ophthalmol; 2007 Jul; 125(7):895-900. PubMed ID: 17620567
[TBL] [Abstract][Full Text] [Related]
17. Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation.
Galor A; Perez VL; Hammel JP; Lowder CY
Ophthalmology; 2006 Dec; 113(12):2317-23. PubMed ID: 16996615
[TBL] [Abstract][Full Text] [Related]
18. Favorable response to high-dose infliximab for refractory childhood uveitis.
Kahn P; Weiss M; Imundo LF; Levy DM
Ophthalmology; 2006 May; 113(5):860-4.e2. PubMed ID: 16545455
[TBL] [Abstract][Full Text] [Related]
19. Humanized anti-interleukin-2 (IL-2) receptor alpha therapy: long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administration.
Nussenblatt RB; Thompson DJ; Li Z; Chan CC; Peterson JS; Robinson RR; Shames RS; Nagarajan S; Tang MT; Mailman M; Velez G; Roy C; Levy-Clarke GA; Suhler EB; Djalilian A; Sen HN; Al-Khatib S; Ursea R; Srivastava S; Bamji A; Mellow S; Sran P; Waldmann TA; Buggage RR
J Autoimmun; 2003 Nov; 21(3):283-93. PubMed ID: 14599854
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of repeated intravenous infusions of an anti-tumor necrosis factor alpha monoclonal antibody, infliximab, in persistently active, refractory juvenile idiopathic arthritis: results of an open-label prospective study.
Gerloni V; Pontikaki I; Gattinara M; Desiati F; Lupi E; Lurati A; Salmaso A; Fantini F
Arthritis Rheum; 2005 Feb; 52(2):548-53. PubMed ID: 15693004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]